| GUILHOT, Joëlle, Michele BACCARANI, Richard E. CLARK, Francisco CERVANTES, François GUILHOT, Andreas HOCHHAUS, Sergei KULIKOV, Jiří MAYER, Andreas L. PETZER, Gianantonio ROSTI, Philippe ROUSSELOT, Giuseppe SAGLIO, Susanne SAUSSELE, Bengt SIMONSSON, Juan-Luis STEEGMANN, Andrey ZARITSKEY a Rüdiger HEHLMANN. Definitions, methodological, and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Online. Blood. Washington DC, USA: American Society of Hematology, 2012, roč. 119, č. 25, s. 5963-5971. ISSN 0006-4971. Dostupné z: https://dx.doi.org/10.1182/blood-2011-10-383711. [citováno 2024-04-23] |
Další formáty:
BibTeX
LaTeX
RIS
@article{982445,
author = {Guilhot, Joëlle and Baccarani, Michele and Clark, Richard E. and Cervantes, Francisco and Guilhot, François and Hochhaus, Andreas and Kulikov, Sergei and Mayer, Jiří and Petzer, Andreas L. and Rosti, Gianantonio and Rousselot, Philippe and Saglio, Giuseppe and Saussele, Susanne and Simonsson, Bengt and Steegmann, JuanandLuis and Zaritskey, Andrey and Hehlmann, Rüdiger},
article_location = {Washington DC, USA},
article_number = {25},
doi = {http://dx.doi.org/10.1182/blood-2011-10-383711},
keywords = {TYROSINE KINASE INHIBITORS; CHRONIC GRANULOCYTIC-LEUKEMIA; PROGRESSION-FREE SURVIVAL; INTERFERON-ALPHA; COMPETING RISKS; PROGNOSTIC DISCRIMINATION; CYTOGENETIC RESPONSE; MOLECULAR RESPONSE; RANDOMIZED-TRIALS; STI571 IRIS},
language = {eng},
issn = {0006-4971},
journal = {Blood},
title = {Definitions, methodological, and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet},
volume = {119},
year = {2012}
}
TY - JOUR
ID - 982445
AU - Guilhot, Joëlle - Baccarani, Michele - Clark, Richard E. - Cervantes, Francisco - Guilhot, François - Hochhaus, Andreas - Kulikov, Sergei - Mayer, Jiří - Petzer, Andreas L. - Rosti, Gianantonio - Rousselot, Philippe - Saglio, Giuseppe - Saussele, Susanne - Simonsson, Bengt - Steegmann, Juan-Luis - Zaritskey, Andrey - Hehlmann, Rüdiger
PY - 2012
TI - Definitions, methodological, and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet
JF - Blood
VL - 119
IS - 25
SP - 5963-5971
EP - 5963-5971
PB - American Society of Hematology
SN - 00064971
KW - TYROSINE KINASE INHIBITORS
KW - CHRONIC GRANULOCYTIC-LEUKEMIA
KW - PROGRESSION-FREE SURVIVAL
KW - INTERFERON-ALPHA
KW - COMPETING RISKS
KW - PROGNOSTIC DISCRIMINATION
KW - CYTOGENETIC RESPONSE
KW - MOLECULAR RESPONSE
KW - RANDOMIZED-TRIALS
KW - STI571 IRIS
N2 - The treatment policy of chronic myeloid leukemia (CML), particularly with tyrosine kinase inhibitors (TKIs), has been influenced by several recent studies that were well designed and rapidly performed, but their interpretation is of some concern because different endpoints and methodologies were used. In order to understand and compare the results of the previous and future studies and to translate their conclusion into clinical practice, there is a need for common definitions and methods for analyses of CML studies. A panel of experts was appointed by the European LeukemiaNet with the aim of developing a set of definitions and recommendations to be used in design, analyses and reporting of phase III clinical trials in this disease. This paper summarizes the consensus of the panel on events and major endpoints of interest in CML. It also focuses on specific issues concerning the intention to treat principle, and longitudinal data analyses in the context of long term follow-up. The panel proposes that future clinical trials follow these recommendations.
ER -
GUILHOT, Jo$\backslash$''elle, Michele BACCARANI, Richard E. CLARK, Francisco CERVANTES, Fran$\backslash$c cois GUILHOT, Andreas HOCHHAUS, Sergei KULIKOV, Jiří MAYER, Andreas L. PETZER, Gianantonio ROSTI, Philippe ROUSSELOT, Giuseppe SAGLIO, Susanne SAUSSELE, Bengt SIMONSSON, Juan-Luis STEEGMANN, Andrey ZARITSKEY a Rüdiger HEHLMANN. Definitions, methodological, and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Online. \textit{Blood}. Washington DC, USA: American Society of Hematology, 2012, roč.~119, č.~25, s.~5963-5971. ISSN~0006-4971. Dostupné z: https://dx.doi.org/10.1182/blood-2011-10-383711. [citováno 2024-04-23]
|
